<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952285</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0215</org_study_id>
    <nct_id>NCT04952285</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of the Loading Dose of Tranexamic Acid in Scoliosis Surgery During Perioperative</brief_title>
  <official_title>The Efficacy and Safety of the Loading Dose of Tranexamic Acid in Scoliosis Surgery During Perioperative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to make full use of the advantage of spinal orthopedic surgery in our&#xD;
      medical center.Analyze the blood loss and blood coagulation function and the influence of&#xD;
      safety of load dose tranexamic acid (TXA) in scoliosis surgery during perioperative.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>Intraoperative blood loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incision drainage Incision drainage Incision drainage after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Incision drainage after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autologous blood doping</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>Recycle the blood during the intraoperative , back to the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>red blood cell transfusion</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>red blood cell transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma infusion</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>Plasma infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HB</measure>
    <time_frame>Within 1 week before surgery；1 day after surgery</time_frame>
    <description>hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WBC</measure>
    <time_frame>Within 1 week before surgery；1 day after surgery</time_frame>
    <description>White blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTL</measure>
    <time_frame>Within 1 week before surgery；1 day after surgery</time_frame>
    <description>platelet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT</measure>
    <time_frame>Within 1 week before surgery；1 day after surgery</time_frame>
    <description>Prothrombin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APTT</measure>
    <time_frame>Within 1 week before surgery；1 day after surgery</time_frame>
    <description>activated partial thromboplastin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>Within 1 week before surgery；1 day after surgery</time_frame>
    <description>International Normalized Ratio</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">207</enrollment>
  <condition>Tranexamic Acid</condition>
  <arm_group>
    <arm_group_label>Normal saline（I）</arm_group_label>
    <description>Intravenous infusion of 0.9% saline when start to cut the skin，do not intravenous tranexamic acid during the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid（II）</arm_group_label>
    <description>Intravenous infusion of tranexamic acid 1g when start to cut the skin in 1 hour</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        age:18-60 years old；American Society of Anesthesiologists (ASA):I-II；The spinal orthopedic&#xD;
        undergoing elective surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age:18-60 years old&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA):I-II&#xD;
&#xD;
          -  The spinal orthopedic undergoing elective surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiopulmonary dysfunction&#xD;
&#xD;
          -  Blood coagulation dysfunction&#xD;
&#xD;
          -  Disorders of liver and kidney function&#xD;
&#xD;
          -  Tranexamic acid allergies&#xD;
&#xD;
          -  The history of pulmonary embolism and venous thrombosis of lower limbs&#xD;
&#xD;
          -  Anticoagulant drugs and nonsteroidal anti-inflammatory drugs in 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>Blood conservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

